• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Molecular Partners Ag ADR (NQ: MOLN )

    5.330 +0.080 (+1.52%)
    Streaming Delayed Price Updated: 2:38 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Molecular Partners Ag ADR

    < Previous 1 2 3 4 5 6 7 Next >
    Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy
    From Molecular Partners
    Via GlobeNewswire
    Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR
    From Molecular Partners
    Via GlobeNewswire
    Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
    From Molecular Partners
    Via GlobeNewswire
    Molecular Partners Publishes Invitation to Annual General Meeting 2023
    From Molecular Partners
    Via GlobeNewswire
    Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022
    From Molecular Partners
    Via GlobeNewswire
    Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
    Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate Buy 
    Via MarketBeat
    Topics Initial Public Offering
    Exposures Securities Market
    Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference
    From Molecular Partners
    Via GlobeNewswire
    Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform
    From Molecular Partners
    Via GlobeNewswire
    Molecular Partners to Present at SVB Leerink Global Healthcare Conference
    From Molecular Partners
    Via GlobeNewswire
    Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia
    From Molecular Partners
    Via GlobeNewswire
    Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference
    From Molecular Partners
    Via GlobeNewswire
    Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML
    From Molecular Partners
    Via GlobeNewswire
    Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting
    - Company will also host a reception with Key Opinion Leaders in New Orleans - 
    From Molecular Partners
    Via GlobeNewswire
    Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences
    From Molecular Partners
    Via GlobeNewswire
    Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End
    From Molecular Partners
    Via GlobeNewswire
    Molecular Partners Announces Planned Departure of Chief Financial Officer
    From Molecular Partners
    Via GlobeNewswire
    Molecular Partners AG (NASDAQ:MOLN) Long Term Investor Alert: Investigation of Potential Wrongdoing
    San Diego, CA -- (SBWIRE) -- 10/26/2022 -- An investigation was announced for current long-term investors in shares of Molecular Partners AG (NASDAQ:MOLN) concerning potential breaches of fiduciary... 
    Via SBWire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Gainers NeuroMetrix (NASDAQ:NURO) shares increased by 23.0% to $3.48 during Monday's pre-market session. The company's market cap stands at $24.8 million. 
    Via Benzinga
    NASDAQ:MOLN Investor Notice: Deadline Coming Up on September 12, 2022 in Lawsuit Against Molecular Partners AG
    San Diego, CA -- (SBWIRE) -- 09/12/2022 -- A deadline is coming up on September 12, 2022 in the lawsuit filed for certain investors of Molecular Partners AG (NASDAQ:MOLN). 
    Via SBWire
    Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Molecular Partners AG (MOLN) Investors of Class Action and Last Few Hours to Actively Participate
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    FINAL INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Molecular Partners AG with Losses of $100,000 to Contact the Firm
    From The Schall Law Firm
    Via Business Wire
    MOLN DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Molecular Partners AG Investors With Losses to Secure Counsel Before Important September 12 Deadline in Securities Class Action - MOLN
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Initial Public Offering Lawsuit
    Exposures COVID-19 Financial Legal
    MOLECULAR PARTNERS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Molecular Partners AG and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Molecular Partners AG Investors to Secure Counsel Before Important Deadline in Securities Class Action - MOLN
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Initial Public Offering Lawsuit
    Exposures COVID-19 Financial Legal
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
      
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
    Upgrades 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
      On Tuesday, 250 stocks hit new 52-week lows. 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
      
    Via Benzinga
    SVB Leerink Slashes Price Target On This Stock By Over 73%, Plus This Analyst Predicts $56 For Toll Brothers
    Citigroup raised the price target for MacroGenics, Inc. (NASDAQ: MGNX) from $13 to $16. MacroGenics shares rose 4.8% to $3.90 in pre-market trading. 
    Via Benzinga
    ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Molecular Partners AG Investors to Secure Counsel Before Important Deadline in Securities Class Action - MOLN
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Initial Public Offering Lawsuit
    Exposures COVID-19 Financial Legal
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.